Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Steroidal mineralocorticoid receptor antagonists reduce morbidity and mortality among patients with heart failure and reduced ejection fraction, but their efficacy in those with heart failure and mildly reduced or preserved ejection fraction has not been established. Data regarding the efficacy and safety of the nonsteroidal mineralocorticoid receptor antagonist finerenone in patients with heart failure and mildly reduced or preserved ejection fraction are needed. METHODS: In this international, double-blind trial, we randomly assigned patients with heart failure and a left ventricular ejection fraction of 40% or greater, in a 1:1 ratio, to receive finerenone (at a maximum dose of 20 mg or 40 mg once daily) or matching placebo, in addition to usual therapy. The primary outcome was a composite of total worsening heart failure events (with an event defined as a first or recurrent unplanned hospitalization or urgent visit for heart failure) and death from cardiovascular causes. The components of the primary outcome and safety were also assessed. RESULTS: Over a median follow-up of 32 months, 1083 primary-outcome events occurred in 624 of 3003 patients in the finerenone group, and 1283 primary-outcome events occurred in 719 of 2998 patients in the placebo group (rate ratio, 0.84; 95% confidence interval [CI], 0.74 to 0.95; P = 0.007). The total number of worsening heart failure events was 842 in the finerenone group and 1024 in the placebo group (rate ratio, 0.82; 95% CI, 0.71 to 0.94; P = 0.006). The percentage of patients who died from cardiovascular causes was 8.1% and 8.7%, respectively (hazard ratio, 0.93; 95% CI, 0.78 to 1.11). Finerenone was associated with an increased risk of hyperkalemia and a reduced risk of hypokalemia. CONCLUSIONS: In patients with heart failure and mildly reduced or preserved ejection fraction, finerenone resulted in a significantly lower rate of a composite of total worsening heart failure events and death from cardiovascular causes than placebo. (Funded by Bayer; FINEARTS-HF ClinicalTrials.gov number, NCT04435626.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Over the past decade, the use of medications that have been demonstrated to be effective in patients with HF with reduced ejection fraction (angiotensin receptor neprilysin inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter 2 [SGLT2] inhibitors) has been evaluated in large-scale trials in patients with HF and mildly reduced ejection fraction and patients with HFpE”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“This level was significantly lower than that in the STEP-HFpEF program (median, ≈470 pg/mL)36 and substantially lower than in other large-scale outcome trials in HFpEF (median 900–1400 pg/mL).3–6”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Of the enrolled participants, 41% had type 2 diabetes.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [303]
The cited source says what the claim attributes to it.
In the citing paper
“The selective nonsteroidal MRA finerenone was examined in the Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% (FINEARTS-HF) trial of people with symptomatic HFpEF (ejection fraction ≥40%) and was found to reduce the risk of”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [303]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Self-citationPitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Self-citationEmpagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Self-citationEplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
Self-citationEffect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Self-citationDapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Claggett, B., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206286 · Cited by 2,884
Self-citationSpironolactone for heart failure with preserved ejection fraction
Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313731 · Cited by 2,809
Self-citationAngiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908655 · Cited by 2,430
Self-citationSotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868
Self-citationCardiovascular events with finerenone in kidney disease and type 2 diabetes
Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110956 · Cited by 1,814
Self-citation
Cited by
Items 701–800 of 892
Navigating unexplained dyspnoea and the role of HFpEF diagnostic scores
Störk, S., & Tokcan, M. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag092
Wen, C.-F., Chuang, M., Wu, V., & Chen, J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1803971 · Cited by 1
“We excluded two articles for the following reasons: one study focused on heart failure (HF) without a CKD subgroup (Solomon et al., 2024), and one study assessed only atrial fibrillation (Afib) risk (Filippatos et al., 2021).”
Endocrine aspects of pharmacotherapy for chronic heart failure
Ждан, В. М., Volchenko, H. V., Babanina, М. Y., Kіtura, Y. M., Tkachenko, M. V., Kyrian, O. A., Ivanitsky, I. V., & Lebed, V. G. (2026) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.22.3.2026.1716
Chronic Kidney Disease in Cardiovascular Pathologies
Obrișcă, B., & Ismail, G. (2026) · Springer eBooks · doi:10.1007/978-3-032-25434-4_4
Geographic Variation in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Makuvire, T. T., Lam, C. S. P., Pabón, M. A., Claggett, B. L., Kulac, I. J., Desai, A. S., Jhund, P. S., Henderson, A. D., Amarante, F., Chen, M., et al. (2026) · JACC Heart Failure · doi:10.1016/j.jchf.2026.103105
Self-citationToole, J., Bae, S., Wutawunashe, C. V., Kim, M. C., & Kodra, A. (2026) · International Journal of Angiology · doi:10.1055/a-2874-9189
Spironolactone or Finerenone for Cardiovascular and Kidney Protection in Patients with Moderate CKD?
Georgianos, P. I., Leptokaridou, E., Kourtidou, C., Kontogiorgos, I., Roumeliotis, A. K., Vaios, V., & Liakopoulos, V. (2026) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-026-00802-y
“…Efficacy and Safety Superior to Placebo in Patients with Heart Failure) recruited patients who had chronic symptomatic HF with mildly reduced or preserved EF with or without concomitant CKD and T2D aiming to detect the treatment effects of finerenone relative to placebo on HF outcomes [15].”
Repairing the Therapeutic Framework of Mineralocorticoid Receptor Signaling in HFpEF
Pepin, M. E. (2026) · Circulation Research · doi:10.1161/circresaha.126.328632
Hsieh, W. C., Henry, B. M., & Édes, I. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70907 · Cited by 1
Aldosterone synthase inhibitors for the treatment of cardiovascular disease
Rossi, G. P., Rossi, F. B., Cignarella, A., & Seccia, T. M. (2026) · Nature Reviews Endocrinology · doi:10.1038/s41574-026-01259-4 · Cited by 4
“However, the FINE-HEART pooled analysis of finerenone RCTs 52–54 showed that cardiovascular and renal risk reduction was only statistically significant in patients with systolic blood pressure above 135 mmHg before treatment 55 , again affirming the importance of lowering blood pressure.”
Das, B. B. (2026) · Annals of Pediatric Cardiology · doi:10.4103/apc.apc_85_26
“[60,61] In adults with HFpEF, ranolazine has shown modest improvements in diastolic function in small studies, [62] while finerenone has demonstrated significant reductions in worsening HF events and cardiovascular (CV) death in the FINEARTS‑HF trial; [61] however, neither therapy has been…”
Saldarriaga, C., & Pitt, B. (2026) · JACC Heart Failure · doi:10.1016/j.jchf.2026.103157
Self-citationGámez, M. A., Bonilla-Palomas, J. L., Esteban-Fernández, A., Mayoral, A. R., Muñiz, J., González-Manzanares, R., Ruiz-Ortiz, M., Anguita-Sánchez, M., & Mesa-Rubio, D. (2026) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2026.502578
Al‐Horani, R. A., & Goyal, N. (2026) · Drugs and Drug Candidates · doi:10.3390/ddc5020033
“Cardiovascular death occurred in 8.1% of patients receiving finerenone compared with 8.7% in the placebo group (hazard ratio 0.93; 95% CI 0.78–1.11) [ 29].”
InfluentialUmanath, K., Dwyer, J. P., & Mentz, R. J. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1845339
“In a prespecified analysis of the FINEARTS-HF trial (NCT04435626) (16), the risk of HK (potassium >5.5 mmol/L) was higher in patients treated with finerenone compared with those receiving placebo across all ejection fraction groups (an approximately 2-fold increase vs. placebo) (92).”
InfluentialZhao, D., Xia, J., Yang, Z., Yong, Y., Wang, L., & Liu, J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1754115 · Cited by 1
Diabetes Mellitus and the Heart
Marx-Schütt, K., Forst, T. M., Birkenfeld, A. L., Zirlik, A., Müller‐Wieland, D., & Marx, N. (2026) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2766-3079
Adding Finerenone to SGLT2 Inhibitors and Long‐Term Kidney Outcomes in Diabetic Kidney Disease
Matsui, M., Nishimoto, M., Kosugi, T., Kitamura, S., Oda, A., Kawakami, M., Itano, A., Uemura, T., Tamaki, H., Tasaki, H., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70934
Martens, P., & Verbrugge, F. H. (2026) · JACC Heart Failure · doi:10.1016/j.jchf.2026.103063
Fudim, M., Ferrante, F., Vorgang, C. M., Rosner, C. M., & Mentz, R. J. (2026) · Future Cardiology · doi:10.1080/14796678.2026.2683489
“…therapies for patients who have HF with preserved ejection fraction (HFpEF) than for those with HFrEF [19], in recent years there have been important advances in HFpEF as well (e.g., sodium glucose cotransporter 2 inhibitors and non-steroidal mineralocorticoid receptor antagonists) [20,21].”
Gámez, M. A., Bonilla-Palomas, J. L., Esteban-Fernández, A., Mayoral, A. R., Muñiz, J., González-Manzanares, R., Ruiz-Ortiz, M., Anguita-Sánchez, M., & Mesa-Rubio, D. (2026) · Revista Clínica Española · doi:10.1016/j.rce.2026.502578
Sambola, A., & Freire, J. L. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag212
Wettersten, N. W., Katz, R., Garimella, P. S., Bullen, A. L., Ascher, S. B., Seegmiller, J. C., Horiuchi, Y., Takaoka, Y., & Ix, J. H. (2026) · Kidney Medicine · doi:10.1016/j.xkme.2026.101428
Hyperkalemia risk and potassium trajectory after finerenone initiation: a real-world cohort study
Hashimoto, N., Sakaguchi, Y., Naito, M., Makino, S., Takashima, A., Miyakawa, H., Okushima, H., Asai, M., & Hayashi, T. (2026) · Clinical and Experimental Nephrology · doi:10.1007/s10157-026-02898-7 · Cited by 2
“Our cohort included patients with more advanced CKD than typical trial participants [1 – 3, 6 ], and the Loop and thiazide diuretics, which have generally been considered protective against hyperkalemia [15], were positively associated with hyperkalemia in our analysis.”
Schupp, T., Goertz, M., Dudda, J., Abumayyaleh, M., Weidner, K., Schmitt, A., Lau, F., Reinhardt, M., Abel, N., Rusnak, J., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.047798
“As patients with malignancies were commonly excluded from randomized controlled trials, 19 the proportion of patients with a history of malignancies in HFrEF (4.3”
InfluentialPolhemus, D. J., Milstone, Z. J., & Hahn, V. S. (2026) · Journal of Cardiac Failure - Intersections · doi:10.1016/j.yjcafi.2026.05.009
JCF in Case You Missed It! Summary of American College of Cardiology (ACC) 2026
Oliveira-Gomes, D. D., HAJDUCZOK, A. G., & Lala, A. (2026) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2026.04.014
Pharmakotherapie der chronischen Herzinsuffizienz
Oexner, R. R., & Frantz, S. (2026) · Kardiologie up2date · doi:10.1055/a-2701-0826
Finerenone after FINEARTS-HF: evidence boundaries and implementation in heart failure with LVEF ≥40%
Feng, S., & Jin, H. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1880045
“In symptomatic HF with LVEF ≥ 40%, structural disease, elevated natriuretic peptides, eGFR ≥ 25 mL/min/1.73 m2, and potassium ≤ 5.0 mmol/L, finerenone reduced the prespecified composite of cardiovascular death and total worsening HF events (RR 0.84, 95% CI 0.74 – 0.95) (12, 13).”
InfluentialPhenotypic Characterization of Unclassified Pulmonary Hypertension
Reddy, Y. N. V., Frantz, R. P., Egbe, A. C., Miranda, W. R., Asokan, A. K., Hassoun, P. M., Hemnes, A. R., Horn, E. M., Leopold, J. A., Rischard, F. P., et al. (2026) · Circulation Heart Failure · doi:10.1161/circheartfailure.125.014480
Liu, C.-H., Chu, T., Yang, S.-M., Wang, Y., Lee, W., Chang, Y.-C., Chen, Y., Chen, Y., Fang, C.-C., Wen, Z.-H., et al. (2026) · Molecular Medicine · doi:10.1186/s10020-026-01532-2
Hiruma, T., Nakanishi, K., Inoue, S., Nomura, S., Yoshida, Y., Dai, Z., Abe, R., Yamada, T., Fujita, K., Katoh, M., et al. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.102863
Villaschi, A., Oreni, M. L., Toccafondi, A., Cusmano, I., Gonnella, S., Gonella, R., Coni, G., Torri, A., Grati, P., Ambrosetti, M., et al. (2026) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2026.101962 · Cited by 1
“[ 9,10]”
Sleep Apnea in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Lu, H. Y., Schneider, S. R., Pabón, M. A., Claggett, B. L., Miao, M. Z., Desai, A. S., Jhund, P. S., Henderson, A. D., Lam, C. S. P., Senni, M., et al. (2026) · JACC Heart Failure · doi:10.1016/j.jchf.2026.103187
Self-citationFinerenone Beyond Diabetic Kidney Disease: Emerging Evidence and Potential Systemic Implications
Almaimani, M. K., & Alamri, S. A. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15134852 · Cited by 1
“Over a median follow-up period of 32 months, finerenone significantly reduced the composite endpoint of total worsening heart failure events and cardiovascular death, an effect primarily driven by fewer hospitalizations for heart failure [35].”
Diastolic dysfunction and diabetes: the DIADAD study—a retrospective cohort study from Liverpool
Wali, L., Abbara, M. A., Ekhelikar, S., Pilling, J., Albouaini, K., & Murray, S. W. (2026) · Postgraduate Medical Journal · doi:10.1093/postmj/qgag079
Lamar, K., Rodriguez, J. P. P., & Sharma, A. R. (2026) · Seminars in Interventional Radiology · doi:10.1055/a-2884-0599
Nie, Z., & Xiong, Q. (2026) · Circulation Heart Failure · doi:10.1161/circheartfailure.126.014373
What’s new in heart failure? June 2026
Markwirth, P., Hoevelmann, J., Tokcan, M., & Haring, B. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag204
Stern, H. J., & Daugherty, L. R. (2026) · Cardiology in the Young · doi:10.1017/s1047951126113596
Cartilage intermediate layer protein (CILP) in cardiac fibrosis: Protective or pathogenic?
Corrales-Terrón, M., Rossi, C., Krause, J., Schroen, B. L. M., Herum, K. M., & van Nieuwenhoven, F. A. (2026) · Matrix Biology · doi:10.1016/j.matbio.2026.102032 · Cited by 1
Zhang, H., Li, M., & Deng, W. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118201 · Cited by 2
Finerenone and Cardiorenal Outcomes: A Narrative Review
Fernandes, W., Tasneem, S., Latif, F., Soussi, Y. E., Saji, A., Jani, A., Fuqaha, F., MOHAMMED, R. U. H., Leiva, D. M., Iliasov, M., et al. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001377
Refaie, M. M. M., Hasan, A. A., Muhammed, A. A., Ibrahim, R. A., Hassan, E. A., Fathy, E., Soliman, A. M., Sherkawy, H. S., Beshay, O. N., Ahmed, A. A.-E., et al. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12163-5
Sudden Death in Cardio-Kidney-Metabolic Patients
Ameri, P., Cannata, A. N., & Pontremoli, R. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.05.031
TGM2-mediated histone serotonylation is an epigenetic cardioprotective mechanism in HFpEFPreprint
Ogawara, R., Misaka, T., Suzuki, Y., Okochi, S., Ichimura, S., Miura, S., Yokokawa, T., Taira, S., Waguri, S., Oikawa, M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.25.734596
HFpEF as a diabetic complication: the central role of microvascular dysfunction
Nagai, Y., Matoba, K., & Nishimura, R. (2026) · Discover Endocrinology and Metabolism · doi:10.1007/s44417-026-00023-6
“In the FINEARTS-HF trial, the nonsteroidal mineralocorticoid receptor antagonist finerenone significantly reduced the composite of worsening HF events and cardiovascular death in patients with mildly reduced or preserved ejection fraction [61].”
Northway, J., Park, J., Mankowitz, K., & Hoque, F. (2026) · Journal of Brown Hospital Medicine · doi:10.56305/001c.163599
Jafar, T. H., Zhu, A., & Ogungbe, O. (2026) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000001173
Reassuring Signals From TOPCAT
Yang, K., & Kim, F. (2026) · JACC Asia · doi:10.1016/j.jacasi.2026.05.023
Health Status in Heart Failure With Preserved Ejection Fraction in Asia
Hamatani, Y., Lam, C. S. P., Claggett, B. L., Desai, A. S., Jhund, P. S., Martinez, F. A., Zannad, F. M., McMurray, J. J. V., Solomon, S. D., & Vaduganathan, M. (2026) · JACC Asia · doi:10.1016/j.jacasi.2026.05.031
Self-citationSpiazzi, B. F., Zingano, C. P., & Vest, A. R. (2026) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2026.06.025
Cardiovascular Drug Access in Australia and New Zealand: New PBS and PHARMAC Listings, 2023–2025
Ciofani, J. L., Puranik, R., Ekmejian, A. A., Allahwala, U. K., Sinhal, S., James-Smith, J., Pepe, S., Lund, M., & Bhindi, R. (2026) · Heart Lung and Circulation · doi:10.1016/j.hlc.2026.06.001 · Cited by 3
Updates in management of cardiorenal syndrome
Chung, I., Chen, M., Anderson, L., & Banerjee, D. (2026) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001209
Fordan, S., Afridi, I., Garza, A., & Collazo-Maldonado, R. L. (2026) · Postgraduate Medicine · doi:10.1080/00325481.2026.2686460
Aldosterone Synthase Inhibition in Diabetes and Cardiorenal Metabolic Disease
Bloomgarden, Z. T. (2026) · Journal of Diabetes · doi:10.1111/1753-0407.70253
Hidden opportunities for the prevention of heart failure: The role of fenofibrate therapyt
Gilyarevskiy, S. R. (2026) · FOCUS Endocrinology · doi:10.62751/2713-0177-2026-7-2-06
Kattamuri, L. P. V., Sharma, K., & Mukherjee, D. (2026) · International Journal of Angiology · doi:10.1055/a-2904-8847
Self-citationNaser, J. A., Copciag, R., Scott, C. G., Ibrahim, H. H., Kennedy, A. M., Egbe, A. C., Michelena, H. I., Pellikka, P. A., Nkomo, V. T., Miranda, W. R., et al. (2026) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2026.06.012
Gustafson, S. E., Patel, S. R., Fudim, M., Mentz, R. J., Sauer, A. J., Lala, A., Harrington, J., Pandey, A., Svetlichnaya, J., Fitzpatrick, J. K., et al. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10653-z
New heart failure treatment approved by NICE
Wilkinson, E. (2026) · BMJ · doi:10.1136/bmj-2026-100305
Álvarez, A. L., Martínez, M. R., Botero, S. R., Álvarez, A. L., Molinero, A. M., Rubio, L. F., Lamigueiro, C. G., Ávila, E. E. R., Rodríguez, J. M. F., Granell, S. B., et al. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-06267-w
“The FINEARTS-HF study indicated that the addition of finerenone to standard therapy significantly reduced the risk of cardio-vascular mortality and HF decompensation events relative to placebo in patients with HFpEF [9].”
InfluentialHeart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review
Voß, F., Goerke, P., Kelm, M., & Polzin, A. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70610
Shi, J., 方玲琳, Cai, X., Wu, H., Yang, X. H., & Wei, L. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1893975
“RCTs such as EMPEROR-Preserved, PARAGON-HF, and FIDELIO-DKD have demonstrated that these three classes of drugs each reduce the risk of heart failure hospitalization or cardiovascular death by approximately 20% – 30% in patients with HFpEF (9 – 11).”
Giannino, F., Colarusso, L., Mancuso, M., Piccione, M. C., Bella, G. D., Micari, A., & Zito, C. (2026) · Journal of Cardiovascular Echography · doi:10.4103/jcecho.jcecho_11_26
Insufficienza cardiaca: gestione perioperatoria
Jendoubi, A., Damy, T., & Mongardon, N. (2026) · EMC - Anestesia-Rianimazione · doi:10.1016/s1283-0771(26)51981-9 · Cited by 1
Simões, M. V., Danzmann, L. C., Martins, S. M., Neto, J. A. D. F., Marcondes‐Braga, F. G., Mourilhe‐Rocha, R., de Albuquerque, D. C., de Oliveira, M. T., & Moura, L. Z. (2026) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250622i
Advances in Research on Patients Complicated with Diabetic Kidney Disease and Heart Failure
周, 思. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1672713
Pompilio, G., Bellomo, C., Malvestiti, F. M., & Aspromonte, N. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03720-2
“…the US Food and Drug Administration (FDA) recently approved finerenone for the treatment of heart failure with mildly reduced or preserved ejection fraction (HFmrEF and HFpEF), on the basis of the results of the phase III FINEARTS-HF trial, published in the New England Journal of Medicine [8].”
Mineralocorticoid Receptor Antagonists for Renoprotection and Cardioprotection in CKD
Iatridi, F., & Theodorakopoulou, M. P. (2026) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-032-29564-4_16
Öztürk, C., Böhm, L., Altintac, E., Vogelhuber, J., Weber, M., Zimmer, S., & Nickenig, G. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvag203 · Cited by 1
MRA-induced eGFR decline—causes, consequences, and context
Girerd, N., & Lund, L. H. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag096
Wu, J., Lee, K.-W., Huang, S.-C., Chang, H.-Y., & Lin, Y. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1837944
Nonsteroidal MRAs for Heart Failure With Preserved Ejection Fraction
Desai, A. S., Vaduganathan, M., & Solomon, S. D. (2026) · JACC Heart Failure · doi:10.1016/j.jchf.2026.103238
Self-citationRaajasekar, S. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-026-07924-0
Andrade‐Bucknor, S., Barforoshi, S., Le, D. E., Lyubarova, R., & Chung, J. (2026) · Current Cardiology Reports · doi:10.1007/s11886-026-02392-2 · Cited by 1
Chronic Kidney Disease-Associated Cardiomyopathy: Mechanisms and Therapeutic Strategies
Grigoriou, K., Lamprou, V., Chatzichidiroglou, A., Theofilis, P., Iliakis, P., Apostolos, A., Ktenopoulos, N., Karagiannidis, E., Antoniadis, A. P., Fragakis, N., et al. (2026) · British Journal of Hospital Medicine · doi:10.31083/bjhm51534
Сироджов, С. М., & Шарифова, Н. Д. (2026) · BULLETIN OF POSTGRADUATE EDUCATION IN HEALTHCARE · doi:10.66269/2414-0252-2026-16-2-275-282
The Drug Update: Recent drug approvals, summer 2026 edition
Treadway, M. T., Marino, A. B., Theroux, J. D., & Drake, E. S. (2026) · The Nurse Practitioner · doi:10.1097/01.npr.0000000000000460
Endocrine regulation of cardiac fibrosis: implications for HFpEF
Chaturvedi, R., & Atreja, S. M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1911465
“…MRA fi nerenone, with high MR selectivity and a favourable tissue-distribution, reduced the composite of worsening heart failure events and cardiovascular death in patients with mildly reduced or preserved ejection fraction, although hyperkalaemia remains an important safety consideration (16 – 19).”
Wu, J.-Y., Lee, K.-W., Huang, S.-C., Chang, H.-Y., & Lin, Y. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-06384-6
“…controlled trial involving 6,001 patients with heart failure with mildly reduced or preserved ejection fraction recently showed that finerenone improved HF–related outcomes (RR, 0.84; 95% CI, 0.74–0.95; P = .007), further supporting its cardiovascular benefits beyond renal protection [33].”
InfluentialMineralocorticoid receptor overactivation in heart failure with preserved ejection fraction
Kobayashi, M., Pitt, B., & Zannad, F. M. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag578
Self-citationHe, C., Zhao, H., Liu, H., Zhao, X., Zhang, M., & Li, J. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1861971
“…has been adopted as a co-primary endpoint in contemporary HFpEF trials, including STEP-HFpEF (semaglutide) and FINEARTS-HF ( fi nerenone) (13, 14), and a Minnesota Living with Heart Failure Questionnaire (MLHFQ) increase of ≥ 5 points is the established minimal clinically important…”
Pack, S. J.-J., Sawant, S., Abhayaratna, C., & Wang, N. (2026) · Heart · doi:10.1136/heartjnl-2026-327872
Stone, G. W., Lindenfeld, J. M., Zile, M. R., Anker, S. D., Rodés‐Cabau, J., Snyder, C., Kar, S., Pfeiffer, M. P., Bayés‐Genís, A., Bax, J. J., et al. (2026) · Circulation Heart Failure · doi:10.1161/circheartfailure.125.014100
Sex Differences in Heart Failure and Takotsubo Cardiomyopathy
Iribarren, A., Merz, C. N. B., & Gulati, M. (2026) · Physiology in health and disease · doi:10.1007/978-3-032-26472-5_20
Lim, S. K., Hwang, Y., Son, J. W., Lee, S., Jung, C. H., Kim, H., Lim, H., Park, S., Kim, J., Youn, J., et al. (2026) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2026.6.e26
MRAs and Race in Heart Failure: An Individual Participant Data Meta-Analysis of Randomized Trials
Butt, J. H., Jhund, P. S., Henderson, A. D., Talebi, A., Vardeny, O., Claggett, B. L., Vaduganathan, M., Desai, A. S., Pfeffer, M. A., Lam, C. S. P., et al. (2026) · Circulation Heart Failure · doi:10.1161/circheartfailure.125.014355 · Cited by 1
Self-citationZhang, Z., Li, L., Yang, M., Chen, W., Xiao, L., Sun, L., & Agarwal, R. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag179
Inciardi, R. M., Ostrominski, J. W., Claggett, B. L., BRINKER, M. D., Filippatos, G., Lay‐Flurrie, J., Glasauer, A., Scalise, A. V., Rossing, P. R., Ruilope, L. M., et al. (2026) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2026.07.023
Self-citationAlhazmi, A. M., Alayoubi, F., Mufti, R. E., & Albulushi, A. (2026) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2026.103423
Chaparro, S. V., & Rivera-Rodríguez, M. (2026) · Springer eBooks · doi:10.1007/978-1-4939-0779-3_192-2
Khidhir, A., & Kalra, D. K. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01451-x
“Addition - ally, the rates of composite kidney outcomes—defined as a sustained decline in eGFR of 50% or more, eGFR below 15 mL/min/1.73 m², or dialysis initiation—were low and did not differ significantly between the groups [ 52, 54].”
InfluentialKamal, M. (2026) · Progress in Pediatric Cardiology · doi:10.1016/j.ppedcard.2026.101977
Regulation of the Mineralocorticoid Receptor in Physiology and Disease
Young, M. J., Fuller, P. J., Meijer, O. C., Cole, T. J., Kanki, M., Yang, J., Ho, Q. V., Karthigan, N., & Heanue, S. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100156
Agarwal, R., Vogt, L., Floege, J., & Zoccali, C. (2026) · Clinical Kidney Journal · doi:10.1093/ckj/sfag280
Khadka, A., Sainthwar, S. S., Agrawal, R., & Shrestha, S. (2026) · doi:10.5005/aijms-11038-0025
韩, 昱. (2026) · Journal of Clinical Personalized Medicine · doi:10.12677/jcpm.2026.54263
Metadata
- Authors
- Solomon, S. D., McMurray, J. J. V., Vaduganathan, M., Claggett, B., Jhund, P. S., Desai, A. S., Henderson, A. D., Lam, C. S. P., Pitt, B., Senni, M., Shah, S. J., Voors, A. A., Zannad, F., Abidin, I. Z., Alcocer-Gamba, M. A., Atherton, J. J., Bauersachs, J., Chang-Sheng, M., Chiang, C.-E., Chioncel, O., Chopra, V., Comin-Colet, J., Filippatos, G., Fonseca, C., Gajos, G., Goland, S., Goncalvesova, E., Kang, S., Katova, T., Kosiborod, M. N., Latkovskis, G., Lee, A. P.-W., Linssen, G. C. M., Llamas-Esperón, G., Mareev, V., Martinez, F. A., Melenovský, V., Merkely, B., Nodari, S., Petrie, M. C., Saldarriaga, C. I., Saraiva, J. F. K., Sato, N., Schou, M., Sharma, K., Troughton, R., Udell, J. A., Ukkonen, H., Vardeny, O., Verma, S., von Lewinski, D., Voronkov, L., Yilmaz, M. B., Zieroth, S., Lay-Flurrie, J., van Gameren, I., Amarante, F., Kolkhof, P., & Viswanathan, P.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Cardiovascular Division, Brigham and Women’s Hospital, and Harvard Medical School, Boston (S.D.S., M.V., B.C., A.S.D.); British Heart Foundation Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow (J.J.V.M., P.S.J., A.D.H., M.C.P.), and Bayer, Reading (J.L.-F.) — both in the United Kingdom; National Heart Centre Singapore and Duke–National University of Singapore, Singapore (C.S.P.L.); University of Michigan School of Medicine, Ann Arbor (B.P.); University of Milano-Bicocca and Papa Giovanni XXIII Hospital, Bergamo (M. Senni), and the Department of Cardiology, University of Brescia, and ASST “Spedali Civili” Hospital, Brescia (S.N.) — all in Italy; Northwestern University Feinberg School of Medicine, Chicago (S.J.S.); University Medical Center Groningen, Groningen (A.A.V.), the Department of Cardiology, Hospital Group Twente, Almelo (G.C.M.L.), and Bayer, Hoofddorp (I.G.) — all in the Netherlands; Université de Lorraine, INSERM Clinical Inv...
- ORCID
- Solomon, Scott D.
- McMurray, John J.V.
- Vaduganathan, Muthiah
- Claggett, Brian
- Jhund, Pardeep S.
- Desai, Akshay S.
- Henderson, Alasdair D.
- Lam, Carolyn S.P.
- Pitt, Bertram
- Senni, Michele
- Shah, Sanjiv J.
- Voors, Adriaan A.
- Zannad, Faiez
- Abidin, Imran Zainal
- Alcocer-Gamba, Marco Antonio
- Atherton, John J.
- Bauersachs, Johann
- Chiang, Chern-En
- Chioncel, Ovidiu
- Chopra, Vijay
- Filippatos, Gerasimos
- Fonseca, Cândida
- Gajos, Grzegorz
- Goland, Sorel
- Kosiborod, Mikhail N.
- Latkovskis, Gustavs
- Lee, Alex Pui-Wai
- Linssen, Gerard C.M.
- Melenovský, Vojtěch
- Merkely, Béla
- Nodari, Savina
- Petrie, Mark C.
- Saldarriaga, Clara Inés
- Saraiva, Jose Francisco Kerr
- Sato, Naoki
- Schou, Morten
- Troughton, Richard
- Udell, Jacob A.
- Ukkonen, Heikki
- Vardeny, Orly
- Verma, Subodh
- von Lewinski, Dirk
- Voronkov, Leonid
- Zieroth, Shelley
- Kolkhof, Peter
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-10-24
- Volume
- 391
- Issue
- 16
- Pages
- 1475-1485
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4402101139
- Cited by
- 893
- References
- 21
- Citations by year
- 2026: 414 · 2025: 398 · 2024: 81
- FWCI
- 268.66
- Type
- journal article
- Language
- en
- Open access
- green
- hal.univ-lorraine.fr
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Jagiellonian University Repository (Jagiellonian University) (submittedVersion, cc-by-nc-nd)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Bayer
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- finerenone, heart failure with mildly reduced ejection fraction, heart failure with preserved ejection fraction, mineralocorticoid receptor antagonists, non-steroidal mineralocorticoid receptor antagonists, cardiovascular mortality, hyperkalemia, hypokalemia, FINEARTS-HF trial, left ventricular ejection fraction, heart failure hospitalization, drug safety
- MeSH terms
- Aged, Aged, 80 and over, Mineralocorticoid Receptor Antagonists, Double-Blind Method, Female, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Naphthyridines, Stroke Volume, Treatment Outcome, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.